DK0687181T3 - Metode til behandling af hepatitis C hos individer, som ikke responderer på interferon-behandling - Google Patents

Metode til behandling af hepatitis C hos individer, som ikke responderer på interferon-behandling

Info

Publication number
DK0687181T3
DK0687181T3 DK94910226T DK94910226T DK0687181T3 DK 0687181 T3 DK0687181 T3 DK 0687181T3 DK 94910226 T DK94910226 T DK 94910226T DK 94910226 T DK94910226 T DK 94910226T DK 0687181 T3 DK0687181 T3 DK 0687181T3
Authority
DK
Denmark
Prior art keywords
individuals
respond
treating hepatitis
interferon therapy
hepatitis
Prior art date
Application number
DK94910226T
Other languages
Danish (da)
English (en)
Inventor
Paul B Chretien
Milton Mutchnick
Original Assignee
Alpha 1 Biomedicals Inc
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/027,500 external-priority patent/US6001799A/en
Application filed by Alpha 1 Biomedicals Inc, Univ Wayne State filed Critical Alpha 1 Biomedicals Inc
Application granted granted Critical
Publication of DK0687181T3 publication Critical patent/DK0687181T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK94910226T 1993-03-05 1994-03-03 Metode til behandling af hepatitis C hos individer, som ikke responderer på interferon-behandling DK0687181T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/027,500 US6001799A (en) 1991-09-13 1993-03-05 Method of treating hepatitis C in non-responders to interferon treatment
PCT/US1994/002320 WO1994020131A1 (en) 1993-03-05 1994-03-03 Method of treating hepatitis c in non-responders to interferon treatment

Publications (1)

Publication Number Publication Date
DK0687181T3 true DK0687181T3 (da) 2001-10-01

Family

ID=21838079

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94910226T DK0687181T3 (da) 1993-03-05 1994-03-03 Metode til behandling af hepatitis C hos individer, som ikke responderer på interferon-behandling

Country Status (17)

Country Link
EP (1) EP0687181B1 (no)
JP (1) JPH06279309A (no)
KR (1) KR100306024B1 (no)
CN (1) CN1072961C (no)
AT (1) ATE204760T1 (no)
AU (1) AU683248B2 (no)
CA (1) CA2157479C (no)
DE (1) DE69428112T2 (no)
DK (1) DK0687181T3 (no)
ES (1) ES2162862T3 (no)
FI (1) FI954127A0 (no)
GR (1) GR3037021T3 (no)
MY (1) MY121198A (no)
NO (1) NO320877B1 (no)
PT (1) PT687181E (no)
SG (1) SG64894A1 (no)
WO (1) WO1994020131A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69632062T2 (de) 1995-11-02 2004-11-18 Schering Corp. Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
WO2002011754A1 (en) * 2000-08-07 2002-02-14 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis c with thymosin and pegylated interferon
DK1613340T3 (da) 2003-03-28 2010-08-30 Sciclone Pharmaceuticals Inc Behandling af aspergillus-infektioner med thymosin alfa 1
RS52377B (sr) * 2006-05-02 2012-12-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Primena timozina 1, samog ili u kombinaciji sa ptx3 ili ganciklovirom, za lečenje infekcije citomegalovirusom
ES2599979T3 (es) * 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
WO2010129947A2 (en) 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
TW224053B (no) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
CN1072961C (zh) 2001-10-17
KR960700741A (ko) 1996-02-24
CA2157479A1 (en) 1994-09-15
CN1092322A (zh) 1994-09-21
ATE204760T1 (de) 2001-09-15
DE69428112T2 (de) 2002-03-21
SG64894A1 (en) 1999-05-25
CA2157479C (en) 2000-08-08
MY121198A (en) 2006-01-28
KR100306024B1 (ko) 2001-11-30
GR3037021T3 (en) 2002-01-31
NO953473L (no) 1995-09-04
FI954127L (fi) 1995-09-04
DE69428112D1 (de) 2001-10-04
ES2162862T3 (es) 2002-01-16
EP0687181B1 (en) 2001-08-29
AU683248B2 (en) 1997-11-06
WO1994020131A1 (en) 1994-09-15
JPH06279309A (ja) 1994-10-04
PT687181E (pt) 2002-01-30
FI954127A7 (fi) 1995-09-04
NO953473D0 (no) 1995-09-04
AU6275994A (en) 1994-09-26
NO320877B1 (no) 2006-02-06
EP0687181A1 (en) 1995-12-20
FI954127A0 (fi) 1995-09-04

Similar Documents

Publication Publication Date Title
DE60142776D1 (de) Behandlung von herpes infektion mit anwendung von immunomodulatore polynukleotide sequenzen
DK0603305T3 (da) Anvendelse af et thymosin til behandling af hepatitis C
WO2001068077A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections
DE69636734D1 (de) Nucleoside mit anti-hepatitis b virus wirksamkeit
DE69233607D1 (de) Peptide, die die zytotoxische T-Lymphozyte Antwort gegen Hepatitis-B-Virus induzieren
DK0687181T3 (da) Metode til behandling af hepatitis C hos individer, som ikke responderer på interferon-behandling
EP0616535A4 (en) PROCESS FOR THE TREATMENT OF VIRAL INFECTIONS.
AR036697A1 (es) Metodo para el tratamiento de la infeccion por virus de hepatitis c en pacientes sin respuesta a tratamiento
DE69902103D1 (de) Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin
AR036698A1 (es) Metodo para el tratamiento de la infeccion por virus de hepatitis c en pacientes sin respuesta a tratamiento
CY1106388T1 (el) Θepαπεια ηπατιτιδας c με θυμοσινη, ιντepφepονη και ριβαβιρινη
KR950702838A (ko) 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4)
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
NO930401D0 (no) Peptider som blokkerer hiv-infeksjoner og metoder for bruk derav
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
EP1143981A4 (en) TREATMENT AND PREVENTION OF HIV AND OTHER VIRUS INFECTIONS
BR112022006913A2 (pt) Métodos para tratar infecções virais de hepatite delta
ECSP982492A (es) Terapia de interferones polietilenglicol, modificados
MY101495A (en) Treatment of diseases caused by viruses